Reported Earnings • Apr 29
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: CN¥0.31 loss per share (improved from CN¥0.34 loss in FY 2024). Revenue: CN¥712.9m (up 16% from FY 2024). Net loss: CN¥203.3m (loss narrowed 10% from FY 2024). Revenue missed analyst estimates by 5.8%. Earnings per share (EPS) also missed analyst estimates by 80%. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Medical Equipment industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Announcement • Apr 28
Peijia Medical Limited, Annual General Meeting, May 29, 2026 Peijia Medical Limited, Annual General Meeting, May 29, 2026, at 09:30 China Standard Time. Location: no.18 yangjiatian road, suzhou industrial park, suzhou, jiangsu province, China Reported Earnings • Mar 27
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: CN¥0.31 loss per share (improved from CN¥0.34 loss in FY 2024). Revenue: CN¥712.9m (up 16% from FY 2024). Net loss: CN¥203.3m (loss narrowed 10% from FY 2024). Revenue missed analyst estimates by 5.6%. Earnings per share (EPS) also missed analyst estimates by 76%. Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 25% growth forecast for the Medical Equipment industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. Announcement • Mar 18
Peijia Medical Announces DCwire Micro Guidewire Receives FDA 510(k) Clearance Peijia Medical announced that its DCwire Micro Guidewire has received 510(k) clearance from the U.S. Food and Drug Administration ("FDA") on March 17, 2026. The product was independently designed and developed by Achieva Medical Limited, a subsidiary of the Company. This milestone represents the first FDA-cleared product in the Company's portfolio and underscores Peijia Medical's continued commitment to innovation in the field of neurointerventional medical devices. The clearance also marks a significant step forward in the Company's global expansion strategy, enabling its entry into the U.S. market. Peijia Medical remains committed to delivering high-quality, innovative medical technologies to patients worldwide and will continue to strengthen its presence in key international markets. Announcement • Mar 13
Peijia Medical Limited to Report Fiscal Year 2025 Results on Mar 25, 2026 Peijia Medical Limited announced that they will report fiscal year 2025 results on Mar 25, 2026 Reported Earnings • Sep 28
First half 2025 earnings released: CN¥0.10 loss per share (vs CN¥0.10 loss in 1H 2024) First half 2025 results: CN¥0.10 loss per share (in line with 1H 2024). Revenue: CN¥353.4m (up 17% from 1H 2024). Net loss: CN¥69.9m (loss narrowed 2.0% from 1H 2024). Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Medical Equipment industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Major Estimate Revision • Aug 29
Consensus EPS estimates fall by 40% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from CN¥804.9m to CN¥779.9m. Losses expected to increase from CN¥0.13 per share to CN¥0.18. Medical Equipment industry in Hong Kong expected to see average net income growth of 41% next year. Consensus price target up from HK$7.84 to HK$9.64. Share price fell 13% to HK$7.41 over the past week. Breakeven Date Change • Aug 26
Forecast breakeven date moved forward to 2026 The 5 analysts covering Peijia Medical previously expected the company to break even in 2027. New consensus forecast suggests losses will reduce by 53% to 2025. The company is expected to make a profit of CN¥3.44m in 2026. Average annual earnings growth of 93% is required to achieve expected profit on schedule. Reported Earnings • Aug 25
First half 2025 earnings released: CN¥0.10 loss per share (vs CN¥0.10 loss in 1H 2024) First half 2025 results: CN¥0.10 loss per share (in line with 1H 2024). Revenue: CN¥353.4m (up 17% from 1H 2024). Net loss: CN¥69.9m (loss narrowed 2.0% from 1H 2024). Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Medical Equipment industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth. Announcement • Aug 12
Peijia Medical Limited to Report First Half, 2025 Results on Aug 22, 2025 Peijia Medical Limited announced that they will report first half, 2025 results on Aug 22, 2025 Announcement • Apr 30
Peijia Medical Limited, Annual General Meeting, May 27, 2025 Peijia Medical Limited, Annual General Meeting, May 27, 2025, at 09:30 China Standard Time. Location: no.18 yangjiatian road, suzhou industrial park, suzhou, jiangsu province, China Announcement • Apr 15
Peijia Medical Limited Receives Confirmation Letter from the National Medical Products Administration of the People's Republic of China Confirms the Acceptance of the Registration Application for Taurustriotm Transcatheter Aortic Valve System The board of directors of Peijia Medical Limited announced that recently, the Company received a confirmation letter from the National Medical Products Administration of the People's Republic of China (the NMPA), confirming the acceptance of the registration application for TaurusTrioTM Transcatheter Aortic Valve ("TAV") system (the "System"). TaurusTrioTM TAV system is developed and manufactured by the Company based on the exclusive license obtained from JenaValve Technology Inc., which is designed for treating patients with native symptomatic severe aortic regurgitation through transfemoral access. The System was accepted by the Special Review and Approval Procedure for Innovative Medical Devices of the NMPA in June 2023 and will enjoy priority in the appraisal and approval procedures during the registration application process. The Company may not be ABLE to ULTIMATically market TaurusTrioTM T AV system is developed and manufactured by The Company based on the exclusive license obtain from JenaValve Technology Inc., which is designed for treat patients with native symptomatic severe Aortic regurgitation through bloodemoral access. The System were accepted by the Special Review and approval Procedure for Innovative Medical Devices. Announcement • Apr 09
Peijia Medical Limited Receives Approval from National Medical Products Administration of the PRC for its Registration Application Peijia Medical Limited announced that YonFlow®? Flow Diverting Stent received the approval from the National Medical Products Administration of the PRC (Guo Jia Yao Pin Jian Du Guan Li Ju) (the "NMPA") for its registration application. YonFlow®? Flow diverting Stent, developed by Jiangsu NowYon Medical Limited ("NowYon Medical"), is the first flow diverting stent system in the globe that can be retrieved after its complete release, which allows users to have precise control over the device during procedures. Meanwhile, the product's cobalt-chrome alloy material provides stronger radial support and good vessel wall apposition. Announcement • Apr 08
Peijia Medical Limited Completes the First Patient Treatment of the First-In-man Clinical Trial of ReachTile™? Robotic-Assisted Transcatheter Aortic Valve Replacement Peijia Medical Limited announced that on April 2, 2025, the Company completed the first patient treatment of the first-in-man clinical trial of ReachTactile™? robotic-assisted transcatheter aortic valve replacement ("TAVR") system. The procedure was performed by Professor Yan Wang and his team in Xiamen Cardiovascular Hospital of Xiamen University, utilizing the ReachTactileTM robotic-assisted TAVR system to implant a TaurusElite®? transcatheter aortic valves in a patient with severe aortic stenosis. ReachTactileTM, the Company's internally developed robotic-assisted TAVR systems, offers an innovative, cost-effective solution for TAVR therapy. The mobile, modular design fits conventional catheter rooms, allowing a single cardiologist to operate multiple devices with sub-millimeter precision. A force-sensing mechanism provides real-time tactile feedback, aiding navigation in complex vascular conditions. The Master Unit-Slave Unit architecture allows cardiologists to reduce radiation exposure and other occupational diseases. Meanwhile, remote control capabilities via ethernet enable long-distance operations and training. Breakeven Date Change • Mar 28
Forecast to breakeven in 2026 The 4 analysts covering Peijia Medical expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 52% to 2025. The company is expected to make a profit of CN¥16.4m in 2026. Average annual earnings growth of 99% is required to achieve expected profit on schedule. Reported Earnings • Mar 27
Full year 2024 earnings: EPS misses analyst expectations Full year 2024 results: CN¥0.34 loss per share (improved from CN¥0.58 loss in FY 2023). Revenue: CN¥615.5m (up 40% from FY 2023). Net loss: CN¥226.6m (loss narrowed 42% from FY 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 39%. Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 25% growth forecast for the Medical Equipment industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Announcement • Mar 13
Peijia Medical Limited to Report Fiscal Year 2024 Results on Mar 25, 2025 Peijia Medical Limited announced that they will report fiscal year 2024 results on Mar 25, 2025 Announcement • Mar 05
Peijia Medical Limited Completes the First Two Implants with the TrilogyTM Transcatheter Heart Valve System The board of directors of Peijia Medical Limited announced the successful completion of the first two implants for treating severe aortic regurgitation with the TrilogyTM Transcatheter Heart Valve ("THV") System in Taiwan, China. TrilogyTM THV System is a licensed-in CE-Mark approved transcatheter aortic valve replacement product. It is indicated for use in patients with symptomatic severe aortic regurgification or symptomatic severe aortic stenosis who are judged by a Heart Team (including a cardiac surgeon), to be at high or greater risk for surgical aortic valve replacement. Announcement • Nov 01
Peijia Medical Limited Announces Resignation of Yu Zhiyun as Non-Executive Director and A Member of the Board's Remuneration Committee The board of directors of Peijia Medical Limited hereby announced that Dr. Yu Zhiyun ("Dr. Yu") has tendered his resignation as a non-executive Director and a member of the Board's Remuneration Committee on November 1, 2024 with immediate effect. Dr. Yu resigned from his position in order to devote more time to his other work commitments. Dr. Yu shall remain as a consultant of the Company. Reported Earnings • Sep 28
First half 2024 earnings released: CN¥0.10 loss per share (vs CN¥0.31 loss in 1H 2023) First half 2024 results: CN¥0.10 loss per share (improved from CN¥0.31 loss in 1H 2023). Revenue: CN¥301.2m (up 34% from 1H 2023). Net loss: CN¥71.3m (loss narrowed 66% from 1H 2023). Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Medical Equipment industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings. Announcement • Sep 05
Peijia Medical Limited, Annual General Meeting, Sep 30, 2024 Peijia Medical Limited, Annual General Meeting, Sep 30, 2024, at 09:30 China Standard Time. Location: no.18 yangjiatian road, suzhou industrial park, suzhou, jiangsu province, China Major Estimate Revision • Aug 30
Consensus EPS estimates upgraded to CN¥0.29 loss The consensus outlook for fiscal year 2024 has been updated. 2024 losses forecast to reduce from -CN¥0.356 to -CN¥0.287 per share. Revenue forecast steady at CN¥633.8m. Medical Equipment industry in Hong Kong expected to see average net income growth of 27% next year. Consensus price target down from HK$6.40 to HK$5.64. Share price rose 5.4% to HK$2.74 over the past week. Reported Earnings • Aug 26
First half 2024 earnings released: CN¥0.10 loss per share (vs CN¥0.31 loss in 1H 2023) First half 2024 results: CN¥0.10 loss per share (improved from CN¥0.31 loss in 1H 2023). Revenue: CN¥301.2m (up 34% from 1H 2023). Net loss: CN¥71.3m (loss narrowed 66% from 1H 2023). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Medical Equipment industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 51% per year, which means it is significantly lagging earnings. Announcement • Aug 14
Peijia Medical Limited to Report First Half, 2024 Results on Aug 23, 2024 Peijia Medical Limited announced that they will report first half, 2024 results on Aug 23, 2024 Announcement • Jul 25
Edwards Lifesciences Corporation (NYSE:EW) has entered into an agreement to acquire JenaValve Technology, Inc. Edwards Lifesciences Corporation (NYSE:EW) has entered into an agreement to acquire JenaValve Technology, Inc. on July 24, 2024. In related transaction Edwards has exercised its option to acquire Endotronix, Inc. In connection with the Edwards 's acquisition of JenaValve and Endotronix, Edwards expects to pay a total upfront purchase price of approximately $1.2 billion in cash at the closing of these acquisitions, plus up to an additional $445 million upon the achievement of certain milestones. The transaction is subject to subject to antitrust regulations. The acquisitions are subject to the satisfaction of certain closing conditions, including the receipt of required antitrust and foreign investment approvals. Reported Earnings • Jun 23
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: CN¥0.58 loss per share (improved from CN¥0.61 loss in FY 2022). Revenue: CN¥441.1m (up 76% from FY 2022). Net loss: CN¥392.5m (loss narrowed 3.7% from FY 2022). Revenue missed analyst estimates by 5.0%. Earnings per share (EPS) also missed analyst estimates by 12%. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Medical Equipment industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has fallen by 56% per year, which means it is significantly lagging earnings. Board Change • Jun 17
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 7 experienced directors. 3 highly experienced directors. 4 independent directors (7 non-independent directors). Independent Non-Executive Director Huacheng Wei was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Announcement • Jun 15
Peijia Medical Limited to Report Fiscal Year 2023 Results on Jun 15, 2024 Peijia Medical Limited announced that they will report fiscal year 2023 results on Jun 15, 2024 Reported Earnings • Mar 30
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: CN¥0.58 loss per share (improved from CN¥0.61 loss in FY 2022). Revenue: CN¥441.1m (up 76% from FY 2022). Net loss: CN¥392.5m (loss narrowed 3.7% from FY 2022). Revenue missed analyst estimates by 5.0%. Earnings per share (EPS) also missed analyst estimates by 12%. Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Medical Equipment industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has fallen by 47% per year, which means it is significantly lagging earnings. Announcement • Mar 16
Peijia Medical Limited to Report Fiscal Year 2023 Results on Mar 28, 2024 Peijia Medical Limited announced that they will report fiscal year 2023 results on Mar 28, 2024 Breakeven Date Change • Mar 07
Forecast to breakeven in 2025 The 3 analysts covering Peijia Medical expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 31% per year to 2024. The company is expected to make a profit of CN¥25.0m in 2025. Average annual earnings growth of 77% is required to achieve expected profit on schedule. Announcement • Jan 29
Peijia Medical Announces Successful Completion of Patient Enrollment for Pivotal TaurusTrio Transcatheter Aortic Regurgitation Clinical Trial Peijia Medical Limited announced the completion of patient enrollment and implantation of the TaurusTrio Transcatheter Aortic Valve Replacement (TAVR) system clinical trial. TaurusTrio is a part of the licensed-in Trilogy Heart Valve System for Aortic Regurgitation (AR) from JenaValve Technology Inc. The multi-center trial utilized the TaurusTrio TAVR system to treat pure AR in 116 patients across 13 hospitals within China and is designed to assess the safety and efficacy of the TAVR system in treating patients with native symptomatic, severe AR, who were deemed to be at high or greater risk for surgical aortic valve replacement. Results of the clinical trial will be included Peijia's future submission of registration application to the National Medical Products Administration (NMPA). In January 2022, Peijia and JenaValve entered into a technology licensing agreement wherein Peijia obtained the exclusive rights to develop and commercialize the Trilogy Heart Valve System in the Greater China region under the TaurusTrio brand. Breakeven Date Change • Sep 04
Forecast to breakeven in 2025 The 5 analysts covering Peijia Medical expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 46% per year to 2024. The company is expected to make a profit of CN¥58.3m in 2025. Average annual earnings growth of 89% is required to achieve expected profit on schedule. Reported Earnings • Sep 02
First half 2023 earnings released: CN¥0.31 loss per share (vs CN¥0.14 loss in 1H 2022) First half 2023 results: CN¥0.31 loss per share (further deteriorated from CN¥0.14 loss in 1H 2022). Revenue: CN¥224.9m (up 89% from 1H 2022). Net loss: CN¥212.1m (loss widened 131% from 1H 2022). Revenue is forecast to grow 39% p.a. on average during the next 3 years, compared to a 32% growth forecast for the Medical Equipment industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 100% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings. Announcement • Aug 19
Peijia Medical Limited to Report First Half, 2023 Results on Aug 31, 2023 Peijia Medical Limited announced that they will report first half, 2023 results on Aug 31, 2023 Buying Opportunity • Aug 15
Now 22% undervalued after recent price drop Over the last 90 days, the stock is down 1.7%. The fair value is estimated to be HK$9.54, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 79% over the last 3 years. Earnings per share has grown by 78%. For the next 3 years, revenue is forecast to grow by 38% per annum. Earnings is also forecast to grow by 57% per annum over the same time period. Announcement • Aug 01
Peijia Medical Limited Announces First Patient in Multi-Center Registration Clinical Trial of Taurustrio™? Transcatheter Aortic Valve Replacement System in China The board of directors of Peijia Medical Limited announced that the Company has enrolled the first patient of the multi-center registration clinical trial for TaurusTrio™? transcatheter aortic valve replacement system, the licensed-in TrilogyTM Heart Valve System for aortic regurgitation from JenaValve Technology Inc. The first implant has been successfully completed by Professor Yongjian Wu and Professor Guangyuan Song in Beijing An Zhen Hospital, Capital Medical University on July 26, 2023. The registration clinical trial of the System is a single-arm, prospective, multi-center study. It is designed to assess the safety and efficacy of the System in treating patients with native symptomatic severe AR, who are judged by a Heart Team (including a cardiac surgeon), to be at high or greater risk for surgical aortic valve replacement. The results of this clinical trial will be included in the Company's future submission of registration application to the National Medical Products Administration (the "NMPA"). In June 2023, the System was formally accepted by the Special Review and Approval Procedure for Innovative Medical Devices of the NMPA. As of the date of this announcement, no transfemoral TAVR product for AR has been approved by the NMPA. Reference is made to the Company's announcement dated January 14, 2022. The Group obtained an exclusive license from JenaValve for developing, manufacturing and commercializing Trilogy™? Heart Valve System in the Greater China region. Reference is also made to the Company's announcement date May 15, 2023. On May 12, 2023, the successful completion of the first two commercial implants with the Trilogy™? Heart Valve System took place in Hong Kong. The Company may not be ABLE to ULTIMATically DEVELOP and market TaurusTrio™? TAVR system SUCCESSF fully. ShareHOLDers of the Company and POTENTIAL INVESTORS are ADVISED to EXERCISE DUE care when DEALING in the shares of the Company. Announcement • Jul 23
Peijia Medical Limited Provides Unaudited Revenue Guidance for the Period from January 1, 2023 to June 30, 2023 Peijia Medical Limited provided unaudited revenue guidance for the period from January 1, 2023 to June 30, 2023. For the period, the company expected revenue to be approximately RMB 220 million to RMB 230 million compared to RMB 118.8 million reported a year ago. New Risk • Jul 16
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: CN¥408m Forecast net loss in 3 years: CN¥2.4m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (CN¥2.4m net loss in 3 years). Significant insider selling over the past 3 months (HK$6.5m sold). Announcement • Jul 08
Peijia Medical Limited Receives Approval from the National Medical Products Administration of the PRC for the Registration Application of DCwireTM Micro Guidewire Peijia Medical Limited announced that on June 29, 2023, the Group received the approval from the National Medical Products Administration of the PRC for the registration application of DCwireTM Micro Guidewire, making it the Group's fifteenth NMPA approved neurointerventional product. DCwire TM Micro Guidewire is a product developed by Achieva Medical Limited ("Achieva"), a wholly-owned subsidiary of the Company, and is designed based on the idea of "microstructure". The term "microstructure" refers to the design of a multi-layered micro-structured device made of multiple materials through precision manufacturing. Due to the thin and tortuous nature of intracranial vessels, devices are required to be controlled and operated through tight spaces, and therefore, there is a heightened demand for precision with respect to the design and manufacturing of such devices. DCwireTM Micro Guidewire has realized the manufacturing precision as well as the unique material properties of "microstructure", which allows the device to be precisely controlled and easy to super select vessels, enabling physicians build vascular access quickly and more easily during procedures. DCwireTM Micro Guidewire is a new-generation neurointerventional micro guidewire developed by Achieva. NMPA approval for the registration application of DCwireTM Micro Guidewire is another significant step for the Company to enhance a well-rounded product portfolio for stroke treatment. Recent Insider Transactions • Apr 21
Executive Director & Company Secretary recently sold HK$3.1m worth of stock On the 17th of April, Hong Ye sold around 280k shares on-market at roughly HK$11.09 per share. This transaction amounted to 2.0% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of HK$9.2m more than they bought in the last 12 months. Breakeven Date Change • Apr 07
Forecast to breakeven in 2025 The 4 analysts covering Peijia Medical expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 43% per year to 2024. The company is expected to make a profit of CN¥24.7m in 2025. Average annual earnings growth of 61% is required to achieve expected profit on schedule. Major Estimate Revision • Apr 06
Consensus EPS estimates fall by 73% The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from CN¥453.1m to CN¥424.5m. Losses expected to increase from CN¥0.39 per share to CN¥0.67. Medical Equipment industry in Hong Kong expected to see average net income growth of 25% next year. Consensus price target broadly unchanged at HK$14.22. Share price was steady at HK$9.94 over the past week. Board Change • Nov 16
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 4 were independent directors. The company's board is composed of: 4 independent directors. 7 non-independent directors. Independent Non-Executive Director Huacheng Wei was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Reported Earnings • Aug 21
First half 2022 earnings released: CN¥0.14 loss per share (vs CN¥0.27 loss in 1H 2021) First half 2022 results: CN¥0.14 loss per share (up from CN¥0.27 loss in 1H 2021). Revenue: CN¥118.8m (up 130% from 1H 2021). Net loss: CN¥92.0m (loss narrowed 48% from 1H 2021). Over the next year, revenue is forecast to grow 104%, compared to a 622% growth forecast for the Medical Equipment industry in Hong Kong. Breakeven Date Change • Jul 13
Forecast to breakeven in 2024 The 3 analysts covering Peijia Medical expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 40% per year to 2023. The company is expected to make a profit of CN¥52.2m in 2024. Average annual earnings growth of 66% is required to achieve expected profit on schedule. Reported Earnings • May 03
Full year 2021 earnings: EPS misses analyst expectations Full year 2021 results: CN¥0.87 loss per share (up from CN¥4.43 loss in FY 2020). Revenue: CN¥136.5m (up 253% from FY 2020). Net loss: CN¥574.2m (loss narrowed 72% from FY 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 37%. Over the next year, revenue is forecast to grow 137%, compared to a 661% growth forecast for the industry in Hong Kong. Board Change • Apr 27
Less than half of directors are independent There are 7 new directors who have joined the board in the last 3 years. Of these new board members, 4 were independent directors. The company's board is composed of: 4 independent directors. 7 non-independent directors. Independent Non-Executive Director Huacheng Wei was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Reported Earnings • Apr 03
Full year 2021 earnings: EPS exceeds analyst expectations Full year 2021 results: CN¥0.86 loss per share (up from CN¥4.43 loss in FY 2020). Revenue: CN¥136.5m (up 253% from FY 2020). Net loss: CN¥574.2m (loss narrowed 72% from FY 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 37%. Over the next year, revenue is forecast to grow 137%, compared to a 557% growth forecast for the industry in Hong Kong. Reported Earnings • Sep 03
First half 2021 earnings released: CN¥0.27 loss per share (vs CN¥8.68 loss in 1H 2020) The company reported a solid first half result with reduced losses, improved revenues and improved control over expenses. First half 2021 results: Revenue: CN¥51.7m (up 263% from 1H 2020). Net loss: CN¥175.2m (loss narrowed 90% from 1H 2020). Reported Earnings • Apr 25
Full year 2020 earnings released: CN¥4.43 loss per share (vs CN¥2.33 loss in FY 2019) Full year 2020 results: Net loss: CN¥2.07b (loss widened 289% from FY 2019). Reported Earnings • Mar 30
Full year 2020 earnings released: CN¥4.43 loss per share (vs CN¥2.26 loss in FY 2019) Full year 2020 results: Net loss: CN¥2.07b (loss widened 289% from FY 2019). Is New 90 Day High Low • Jan 20
New 90-day high: HK$31.55 The company is up 15% from its price of HK$27.40 on 22 October 2020. The Hong Kong market is up 19% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Medical Equipment industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is HK$40.06 per share. Is New 90 Day High Low • Nov 17
New 90-day low: HK$22.40 The company is down 19% from its price of HK$27.50 on 19 August 2020. The Hong Kong market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 14% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is HK$60.63 per share. Is New 90 Day High Low • Oct 29
New 90-day low: HK$24.65 The company is down 19% from its price of HK$30.50 on 31 July 2020. The Hong Kong market is up 1.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Medical Equipment industry, which is down 20% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is HK$61.40 per share. 
